Video

Cytiva Cell & Gene Tech Expo August 2025: Gene Therapy

Source: Cytiva

As the convergence of CRISPR-based gene editing and lipid nanoparticle (LNP) delivery systems reshapes the future of precision medicine, Cytiva is leading the way. Our ionizable lipid portfolio and pre-optimized lipid compositions have demonstrated efficient in vivo delivery of CRISPR payloads, supporting both base and gene editing applications. With advanced analytics capable of distinguishing multiple mRNAs and similarly sized guide RNAs within a single LNP, developers can streamline candidate selection and accelerate proof-of-concept studies.

Explore how access to expert formulation collaborators, optimized LNP systems, and cutting-edge analytics can fast-track your gene editing therapeutic development.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Cytiva